Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | BCL2A1 | Q16548 | 6/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.47 |
| ▸ | EIF4E | P06730 | 1/20 | 0.43 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.43 |
| ▸ | MAFG | O15525 | 1/20 | 0.42 |
| ▸ | YWHAZ | P63104 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22802822 | 0.96 | ESR1 (0.52) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL26420998 | 0.93 | CTNNB1 (0.49) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL20694604 | 0.93 | ESR1 (0.52) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL22802820 | 0.92 | ESR1 (0.50) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL24919561 | 0.92 | ESR1 (0.50) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL24919560 | 0.92 | ESR1 (0.50) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL20694567 | 0.92 | ESR1 (0.53) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL24918851 | 0.90 | CTNNB1 (0.49) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL26421014 | 0.90 | CTNNB1 (0.49) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL20694606 | 0.90 | ESR1 (0.51) | ESR1ESR2ACE2BCL2A1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, CD47, CD2 | ESR1 1324/4885ESR2 2635/4885ACE2 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.